AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31505954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength-based exercises (once a day for six weeks)
Number of subjects: 82
Study 31505954 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps femoris strength-based exercises (control group)
Number of subjects: 82
Study 30711291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate (e.max CAD)
Number of subjects: 64
Study 30711291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia-reinforced lithium silicate (Vita Suprinity)
Number of subjects: 64
Study 30711291 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-infiltrated ceramic (Vita Enamic)
Number of subjects: 64
Study 30711291 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (Telio CAD)
Number of subjects: 64
Study 30711291 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (Telio CAD) without thermomechanical fatigue
Number of subjects: 64
Study 28218380 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLA Activity Score
Number of subjects: 38
Study 28218380 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris Hip Score (HHS)
Number of subjects: 38
Study 25417130 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted procedure
Number of subjects: 100
Study 25417130 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 100
Study 25417130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 23223121 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulation current threshold (0.3-0.5 mA, n = 103)
Number of subjects: 205
Study 23223121 — intervention group
Group type: COMPARATOR
Intervention: High stimulation current threshold (0.9-1.1 mA, n = 102)
Number of subjects: 205
Study 21574157 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration (post-HDF)
Number of subjects: 15
Study 21574157 — intervention group
Group type: COMPARATOR
Intervention: Reverse mid-dilution hemodiafiltration (MD-HDF)
Number of subjects: 15
Study 19593248 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate pneumococcal vaccine (PnCRM7)
Number of subjects: 410
Study 19593248 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine randomized communities
Number of subjects: 410
Study 16420549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐oestradiol (tE2, n = 33)
Number of subjects: 152
Study 16420549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐oestradiol (oE2, n = 37)
Number of subjects: 152
Study 16420549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐oestradiol combined with gestodene (oE2 + G, n = 33)
Number of subjects: 152
Study 16420549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152
Study 15327582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) oral morphine sulphate
Number of subjects: 30
Study 15327582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) oral oxycodone hydrochloride
Number of subjects: 30
Study 15327582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.25 mg kg(‐1) morphine sulphate with 0.25 mg kg(‐1) oxycodone hydrochloride
Number of subjects: 30
Study 11151169 — intervention group
Group type: COMPARATOR
Intervention: Two follow-up visits (first day and one month)
Number of subjects: 106
Study 11151169 — intervention group
Group type: EXPERIMENTAL
Intervention: Three postoperative visits (first day, one week and one month)
Number of subjects: 106
Study 9060557 — intervention group
Group type: EXPERIMENTAL
Intervention: < or = 10,000/microL
Number of subjects: 78
Study 9060557 — intervention group
Group type: COMPARATOR
Intervention: < or = 20,000/microL
Number of subjects: 78
Study 8375543 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LA depot)
Number of subjects: 0
Study 8375543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3946435 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 96
Study 3946435 — intervention group
Group type: COMPARATOR
Intervention: Double-contrast barium meal test
Number of subjects: 96
Study 30362457 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cortex response in individuals with ASD
Number of subjects: 0
Study 30362457 — intervention group
Group type: COMPARATOR
Intervention: Auditory cortex response in NT controls
Number of subjects: 0
Study 30362457 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with ASD symptom severity
Number of subjects: 0
Study 27246602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment
Number of subjects: 19
Study 27246602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 25636858 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Inhalation Mode (TIM)
Number of subjects: 18
Study 25636858 — intervention group
Group type: COMPARATOR
Intervention: Tidal Breathing Mode (TBM)
Number of subjects: 18
Study 23066926 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate FAP training
Number of subjects: 16
Study 23066926 — intervention group
Group type: COMPARATOR
Intervention: Waitlist training
Number of subjects: 16
Study 21911726 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (75/50/500 mg/m² every 3 weeks)
Number of subjects: 3298
Study 21911726 — intervention group
Group type: COMPARATOR
Intervention: AC (60/600 mg/m² every 3 weeks) followed by docetaxel at 100 mg/m² every 3 weeks (AC>T)
Number of subjects: 3298
Study 18159093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/daily, n=176)
Number of subjects: 353
Study 18159093 — intervention group
Group type: COMPARATOR
Intervention: Not receiving pravastatin (n=177)
Number of subjects: 353
Study 18159093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/daily)
Number of subjects: 353
Study 18159093 — intervention group
Group type: COMPARATOR
Intervention: Not receiving pravastatin
Number of subjects: 353
Study 16371775 — intervention group
Group type: EXPERIMENTAL
Intervention: Older donor corneal tissue
Number of subjects: 0
Study 16371775 — intervention group
Group type: COMPARATOR
Intervention: Younger donor corneal tissue
Number of subjects: 0
Study 14658746 — intervention group
Group type: EXPERIMENTAL
Intervention: High-prime condition (stereotype words associated with Yellow Peril)
Number of subjects: 69
Study 14658746 — intervention group
Group type: COMPARATOR
Intervention: Low-prime condition (neutral words)
Number of subjects: 69
Study 11002384 — intervention group
Group type: EXPERIMENTAL
Intervention: STAEST margarine
Number of subjects: 34
Study 11002384 — intervention group
Group type: EXPERIMENTAL
Intervention: STEEST margarine
Number of subjects: 34
Study 11002384 — intervention group
Group type: COMPARATOR
Intervention: Control (no added stanols or sterols)
Number of subjects: 34
Study 9113945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat diet with individualized dietary counseling
Number of subjects: 1062
Study 9113945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat diet
Number of subjects: 1062
Study 9113945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study 1633064 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 7
Study 1633064 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg) with intravenous frusemide (20 mg)
Number of subjects: 7
Study 1633064 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (1 ng kg‐1 min‐1) after captopril pretreatment
Number of subjects: 7
Study 1633064 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (20 mg)
Number of subjects: 7
Study 3466465 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-absorbing intraocular lenses (IOLs)
Number of subjects: 0
Study 3466465 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior chamber intraocular lenses (IOLs)
Number of subjects: 0
Study 3466465 — intervention group
Group type: COMPARATOR
Intervention: Normal age-matched observers
Number of subjects: 0
Study 30394065 — intervention group
Group type: EXPERIMENTAL
Intervention: PI+Smith
Number of subjects: 57
Study 30394065 — intervention group
Group type: COMPARATOR
Intervention: Manual Control (MC)
Number of subjects: 57
Study 28947790 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep
Number of subjects: 86
Study 28947790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restricted to 3 hours
Number of subjects: 86
Study 25791143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth service model (6 sessions over 22 weeks of combined pharmacotherapy and caregiver behavior training)
Number of subjects: 223
Study 25791143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth service model
Number of subjects: 223
Study 25791143 — intervention group
Group type: COMPARATOR
Intervention: Control service delivery model (treatment with PCPs augmented with telepsychiatry consultation)
Number of subjects: 223
Study 22882647 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 F × 24 cm Contour(TM) stent
Number of subjects: 162
Study 22882647 — intervention group
Group type: COMPARATOR
Intervention: multi-length 6 F × 22-30 cm Contour VL(TM) stent
Number of subjects: 162
Study 22882647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 162
Study 21059663 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistive exercises for lower limbs and balance training for six weeks
Number of subjects: 23
Study 21059663 — intervention group
Group type: COMPARATOR
Intervention: Regular activities (control)
Number of subjects: 23
Study 19137230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 191
Study 19137230 — intervention group
Group type: COMPARATOR
Intervention: Open colposuspension
Number of subjects: 191
Study 17302515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified mineral water (1000 mL/day)
Number of subjects: 74
Study 17302515 — intervention group
Group type: COMPARATOR
Intervention: Normal mineral water (control)
Number of subjects: 74
Study 14762837 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced intraoperative ultrasonography (CE-IOUS)
Number of subjects: 16
Study 14762837 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ultrasonography (IOUS)
Number of subjects: 16
Study 12588812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 12588812 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 0
Study 12588812 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy
Number of subjects: 0
Study 12588812 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 0
Study 12588812 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH and laser therapy
Number of subjects: 0
Study 9520244 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐Management Program (CPSMP); 12-hour intervention
Number of subjects: 110
Study 9520244 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group; 3-month wait
Number of subjects: 110
Study 7927562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama (controlled breathing practice)
Number of subjects: 0
Study 7927562 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3289502 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 + 5-FU
Number of subjects: 97
Study 3289502 — intervention group
Group type: COMPARATOR
Intervention: 5-FU
Number of subjects: 97
Study 31967190 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Group (200ml carbohydrate- and protein-enriched liquid)
Number of subjects: 80
Study 31967190 — intervention group
Group type: COMPARATOR
Intervention: Control Group (200ml inert solution)
Number of subjects: 80
Study 29382403 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma stress at baseline
Number of subjects: 186
Study 29382403 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame and self-contempt at baseline
Number of subjects: 186
Study 28169879 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week induction/consolidation not followed by reinduction
Number of subjects: 563
Study 28169879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin at 25 mg/m administered 11 times throughout the treatment
Number of subjects: 563
Study 28169879 — intervention group
Group type: COMPARATOR
Intervention: Standard-risk group regimen with reinduction therapy
Number of subjects: 563
Study 28169879 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk group regimen
Number of subjects: 563
Study 28169879 — intervention group
Group type: COMPARATOR
Intervention: High-risk group regimen
Number of subjects: 563
Study 28169879 — intervention group
Group type: COMPARATOR
Intervention: Extremely high-risk group regimen
Number of subjects: 563
Study 25044635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistent(®) absorbable polymer sirolimus‐eluting stent (APSES)
Number of subjects: 29
Study 25044635 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor(®) zotarolimus‐eluting stent (ZES)
Number of subjects: 29
Study 25044635 — intervention group
Group type: COMPARATOR
Intervention: 1st‐gen sirolimus‐eluting stent (SES)
Number of subjects: 29
Study 23320402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB)
Number of subjects: 46
Study 23320402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 46
Study 21366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy intervention using a software application to data mine pharmacy dispensing records and provide educational material to patients.
Number of subjects: 718
Study 21366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy intervention (same as above).
Number of subjects: 718
Study 19052958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 121
Study 19052958 — intervention group
Group type: COMPARATOR
Intervention: Lind fundoplication
Number of subjects: 121
Study 19052958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 121
Study 16500579 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (International Normalized Ratio 2.5-3)
Number of subjects: 2860
Study 16500579 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg)
Number of subjects: 2860
Study 16500579 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2860
Study 16500579 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2860
Study 15606957 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact skin moisture measurement using near-infrared spectroscopy
Number of subjects: 0
Study 15606957 — intervention group
Group type: COMPARATOR
Intervention: Capacitance method
Number of subjects: 0
Study 11335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based smoking cessation curriculum (n = 35)
Number of subjects: 74
Study 11335771 — intervention group
Group type: COMPARATOR
Intervention: Informational pamphlet (n = 39)
Number of subjects: 74
Study 11335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational pamphlet followed by classroom intervention (n = 39)
Number of subjects: 74
Study 9272138 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE with rhG-CSF
Number of subjects: 64
Study 9272138 — intervention group
Group type: COMPARATOR
Intervention: CODE alone
Number of subjects: 64
Study 8387607 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus cisplatin (75 mg/m2), cyclophosphamide (400 mg/m2), and mitomycin (10 mg/m2) given intravenously at 3-week intervals
Number of subjects: 102
Study 8387607 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 102
Study 3065356 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal chorionic villus sampling
Number of subjects: 639
Study 3065356 — intervention group
Group type: COMPARATOR
Intervention: Transcervical chorionic villus sampling
Number of subjects: 639
Study 29690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based policy recommendation document
Number of subjects: 3
Study 29690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based policy recommendation document with support from a knowledge broker
Number of subjects: 3
Study 29690882 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control group
Number of subjects: 3
Study 28870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg capsules self-administered vaginally daily until 36 weeks gestation or delivery)
Number of subjects: 0
Study 28870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary (placed during vaginal examination until 36 weeks gestation or delivery)
Number of subjects: 0
Study 28870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 0
Study 28870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 0
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged isofurans in the highest quartile
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartiles of hsCRP
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartiles of IL-6
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hsCRP in the highest quartiles
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 in the highest quartiles
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline isofurans in the highest quartiles
Number of subjects: 165
Study 26045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline F2-isoprostanes quartile
Number of subjects: 165
Study 23633700 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 percent benzocaine gel
Number of subjects: 576
Study 23633700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent benzocaine gel
Number of subjects: 576
Study 23633700 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (placebo)
Number of subjects: 576
Study 22010225 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 µg/kg of vitamin D(3)
Number of subjects: 54
Study 22010225 — intervention group
Group type: COMPARATOR
Intervention: Control 1 (early age control)
Number of subjects: 54
Study 22010225 — intervention group
Group type: COMPARATOR
Intervention: Control 2
Number of subjects: 54
Study 22010225 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% FOS
Number of subjects: 54
Study 22010225 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% FOS
Number of subjects: 54
Study 18971554 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (100 mg tablet per day)
Number of subjects: 79
Study 18971554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16711849 — intervention group
Group type: EXPERIMENTAL
Intervention: Global network analysis of multichannel EEGs
Number of subjects: 11
Study 16711849 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum spanning tree method for EEG analysis
Number of subjects: 11
Study 14769755 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopy
Number of subjects: 20
Study 14769755 — intervention group
Group type: COMPARATOR
Intervention: Flexible bronchoscopy
Number of subjects: 20
Study 11408881 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric vacuum curettage
Number of subjects: 114
Study 11408881 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspirator
Number of subjects: 114
Study 11408881 — intervention group
Group type: COMPARATOR
Intervention: Electric vacuum curettage by residents
Number of subjects: 114
Study 11408881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Electric vacuum curettage and Manual vacuum aspirator)
Number of subjects: 114
Study 11408881 — intervention group
Group type: COMPARATOR
Intervention: Residents and faculty performing abortions
Number of subjects: 114
Study 8989341 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (1 mg/kg in 2 mL of saline)
Number of subjects: 9
Study 8989341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL of saline)
Number of subjects: 9
Study 8480077 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline therapy after vitamin B6 supplementation
Number of subjects: 15
Study 8480077 — intervention group
Group type: COMPARATOR
Intervention: Theophylline therapy after placebo
Number of subjects: 15
Study 3547879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (20 mg)
Number of subjects: 14
Study 3547879 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporine
Number of subjects: 14
Study 31845112 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk youth
Number of subjects: 0
Study 31845112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-risk youth
Number of subjects: 0
Study 31371616 — intervention group
Group type: EXPERIMENTAL
Intervention: DS‐Cav1 (stabilized subunit vaccine candidate)
Number of subjects: 0
Study 28760535 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 4% ethanol
Number of subjects: 32
Study 28760535 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 20% ethanol
Number of subjects: 32
Study 28760535 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 40% ethanol
Number of subjects: 32
Study 28760535 — intervention group
Group type: COMPARATOR
Intervention: 18.8 mg dose of AMP XR-ODT with deionized water
Number of subjects: 32
Study 26185766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscularly administered drotaverine hydrochloride (40 mg)
Number of subjects: 230
Study 26185766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drotaverine)
Number of subjects: 230
Study 23384160 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0
Study 23384160 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 21387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of 0.5 mg metolazone
Number of subjects: 0